IMMX Immix Biopharma5.23-0.33 (-5.9%)
IMMX Immix Biopharma2.91+0.15 (+5.4%)
Premarket Decliner
IMMX Immix Biopharma2.90+0.04+1.4%
Premarket:2.25-0.65 (-22.4%)
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab
Globe NewswireWed, 3-May 8:00 AM
Premarket Gainer
IMMX Immix Biopharma3.56+0.30+9.2%
Premarket:5.15+1.59 (+44.7%)
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
Globe NewswireMon, 3-Jan 8:00 AM